Amended Statement of Beneficial Ownership (sc 13d/a)
July 22 2015 - 10:18AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.
20549
SCHEDULE 13D
Under the
Securities Exchange Act of 1934
(Amendment No. 4)*
NUTRASTAR INTERNATIONAL
INC.
(Name of Issuer)
COMMON STOCK, PAR VALUE $0.001 PER SHARE
(Title
of Class of Securities)
67060M 107
(CUSIP Number)
Richard E. Fearon, Jr.
Accretive Capital
Management, LLC
16 Wall Street, 2nd Floor
Madison, Connecticut 06443
(203)
482-5805
(Name, Address and Telephone Number of Person
Authorized
to Receive Notices and Communications)
July 16, 2015
(Date of Event which
Requires Filing of This Statement)
If the filing person has previously filed a statement on
Schedule 13G to report the acquisition that is the subject of this Schedule 13D,
and is filing this schedule because of §§240.13d -1(e), 240.13d -1(f) or 240.13d
-1(g), check the following box. [ ]
Note: Schedules filed in paper format shall include a
signed original and five copies of the schedule, including all exhibits. See
Rule 13d-7 for other parties to whom copies are to be sent.
* The remainder of this cover page shall be filled out for a
reporting person’s initial filing on this form with respect to the subject class
of securities, and for any subsequent amendment containing information which
would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page
shall not be deemed to be “filed” for the purpose of Section 18 of the
Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities
of that section of the Act but shall be subject to all other provisions of the
Act (however, see the Notes).
1.
|
NAMES OF REPORTING
PERSONS
IRS IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Accretive Capital Partners, LLC |
2.
|
CHECK THE APPROPRIATE BOX
IF A MEMBER OF A GROUP
|
(a) [_]
(b) [_]
|
3.
|
SEC USE ONLY
|
4.
|
SOURCE OF FUNDS
WC
|
5.
|
CHECK BOX IF DISCLOSURE OF
LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEM 2(e) or 2(f)
|
[_]
|
6.
|
CITIZENSHIP OR PLACE OF
ORGANIZATION
Illinois |
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH |
7.
|
SOLE VOTING POWER
|
8.
|
SHARED VOTING POWER 2,078,356 shares of Common Stock (1)
|
9.
|
SOLE DISPOSITIVE POWER
|
10.
|
SHARED DISPOSITIVE POWER
2,078,356 shares of Common Stock (1)
|
11.
|
AGGREGATE AMOUNT
BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,078,356 shares of
Common Stock (1) |
12.
|
CHECK BOX IF THE AGGREGATE
AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES |
[
] |
13.
|
PERCENT OF CLASS
REPRESENTED BY AMOUNT IN ROW (11)
11.86%(1)(2)
|
14.
|
TYPE OF REPORTING PERSON
CO |
|
|
(1) |
Includes (a) 1,600,856 shares of the common stock, par
value $0.001 per share (the “Common Stock”) of Nutrastar International
Inc. (the “Company”) held directly by Accretive Capital Partners, LLC
(“Accretive Capital Partners”), of which Accretive Capital Management, LLC
(“Accretive Capital Management”) is the manager and Richard E. Fearon Jr.
(“Mr. Fearon”) is the managing partner of Accretive Capital Management and
(b) 477,500 shares of Common Stock that Accretive Capital Partners may
acquire upon the conversion of 47,750 shares of Series A Preferred Stock,
par value $0.001 per share of the Company (the “Series A Preferred Stock”)
at any time, on a one-for-ten basis, at the option of Accretive Capital
Partners. However, the conversion of Series A Preferred Stock is subject
to Section 4(f) of the Certificate of Designation setting forth the
designation and rights of the Series A Preferred Stock, under which, the
number of shares of the Common Stock outstanding immediately after giving
effect to the issuance of shares of Common Stock issuable upon conversion
of Series A Preferred Stock held by Accretive Capital Partners cannot be
more than 9.99%. |
|
|
|
|
|
|
(2) |
All percentages set forth in this Schedule 13D/A are
based upon 17,039,951 shares of Common Stock outstanding as of the date of
this Schedule 13D/A. |
2
1.
|
NAMES OF REPORTING
PERSONS
IRS IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Accretive Capital Management, LLC |
2.
|
CHECK THE APPROPRIATE BOX
IF A MEMBER OF A GROUP
|
(a) [_]
(b) [_]
|
3.
|
SEC USE ONLY
|
4.
|
SOURCE OF FUNDS
WC
|
5.
|
CHECK BOX IF DISCLOSURE OF
LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(e) or 2(f)
|
[_]
|
6.
|
CITIZENSHIP OR PLACE OF
ORGANIZATION
Illinois |
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
|
7.
|
SOLE VOTING POWER
|
8.
|
SHARED VOTING POWER 2,078,356 shares of Common Stock (1)
|
9.
|
SOLE DISPOSITIVE POWER
|
10.
|
SHARED DISPOSITIVE POWER
2,078,356 shares of Common Stock (1)
|
11.
|
AGGREGATE AMOUNT
BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,078,356 shares of
Common Stock (1) |
12.
|
CHECK BOX IF THE AGGREGATE
AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES |
[_] |
13.
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
11.86%(1)(2)
|
14.
|
TYPE OF REPORTING PERSON
CO |
| |
(1) |
Includes (a) 1,600,856 shares of the Common Stock of the
Company held directly by Accretive Capital Partners, of which Accretive
Capital Management is the manager and Mr. Fearon is the managing partner
of Accretive Capital Management and (b) 477,500 shares of Common Stock
that Accretive Capital Partners may acquire upon the conversion of 47,750
shares of Series A Preferred Stock at any time, on a one-for-ten basis, at
the option of Accretive Capital Partners. However, the conversion of
Series A Preferred Stock is subject to Section 4(f) of the Certificate of
Designation setting forth the designation and rights of the Series A
Preferred Stock, under which, the number of shares of the Common Stock
outstanding immediately after giving effect to the issuance of shares of
Common Stock issuable upon conversion of Series A Preferred Stock held by
Accretive Capital Partners cannot be more than 9.99%. |
| |
|
|
| |
(2) |
All percentages set forth in this Schedule 13D/A are
based upon 17,039,951 shares of Common Stock outstanding as of the date of
this Schedule 13D/A. |
3
1.
|
NAMES OF REPORTING PERSONS
IRS IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Richard E. Fearon, Jr. |
| 2. |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A
GROUP |
(a) [_]
(b) [_]
|
3.
|
SEC USE ONLY
|
4.
|
SOURCE OF FUNDS
PF
|
5.
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS
REQUIRED PURSUANT
TO ITEM 2(e) or 2(f)
|
[_]
|
6.
|
CITIZENSHIP OR PLACE OF ORGANIZATION
United States |
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
|
7.
|
SOLE VOTING POWER
2,187,556 shares of Common Stock (1)
|
8.
|
SHARED VOTING POWER
|
9.
|
SOLE DISPOSITIVE POWER
2,187,556 shares of Common Stock (1)
|
10.
|
SHARED DISPOSITIVE POWER
|
11.
|
AGGREGATE AMOUNT
BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,187,556 shares of
Common Stock (1) |
12.
|
CHECK BOX IF THE AGGREGATE
AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES |
[_] |
13.
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
12.49%(1)(2)
|
14.
|
TYPE OF REPORTING PERSON
IN |
| |
(1) |
Includes (a) 109,200 shares of Common Stock held directly
by Mr. Fearon, among which, 40,000 shares are restricted shares granted
pursuant to the Company’s 2009 Equity Incentive Plan, as amended, and vest
in equal installments on a semi-annual basis over a two-year period
beginning on February 15, 2015; (b) 1,600,856 shares of the Common Stock
of the Company held directly by Accretive Capital Partners, of which
Accretive Capital Management is the manager and Mr. Fearon is the managing
partner of Accretive Capital Management and (b) 477,500 shares of Common
Stock that Accretive Capital Partners may acquire upon the conversion of
47,750 shares of Series A Preferred Stock at any time, on a one-for-ten
basis, at the option of Accretive Capital Partners. However, the
conversion of Series A Preferred Stock is subject to Section 4(f) of the
Certificate of Designation setting forth the designation and rights of the
Series A Preferred Stock, under which, the number of shares of the Common
Stock outstanding immediately after giving effect to the issuance of
shares of Common Stock issuable upon conversion of Series A Preferred
Stock held by Accretive Capital Partners cannot be more than
9.99%. |
| |
|
|
| |
(2) |
All percentages set forth in this Schedule 13D/A are
based upon 17,039,951 shares of Common Stock outstanding as of the date of
this Schedule 13D/A. |
4
Item 1. Security and Issuer.
This Amendment No. 4 to Schedule 13D (“Amendment No. 4”)
relates to the shares of common stock, $0.001 par value per share (the “Common
Stock’) of Nutrastar International Inc., a Nevada corporation (the “Company”),
which has its principal executive offices at 4/F Yushan Plaza, 51 Yushan Road,
Nangang District, Harbin 150090, People’s Republic of China.
This Amendment No. 4 is being filed jointly by Accretive
Capital Partners, Accretive Capital Management and Mr. Fearon (collectively, the
"Reporting Persons") to amend and supplement the Items set forth below of the
Schedule 13D previously filed with the Securities and Exchange Commission (the
"SEC") on December 6, 2012, as amended on July 9, 2013, January 2, 2014, and
June 23, 2014 (collectively, "Schedule 13D"). Except as provided herein, this
Amendment No. 4 does not modify any of the information previously reported on
the Schedule 13D.
Item 3. Source and Amount of Funds or Other Consideration.
Item 3 of Schedule 13D is hereby amended and supplemented by
the following:
Funds used for the purchase of 11,425 shares of Common Stock on
the open market reported herein under Item 4 were derived from available working
capital of Accretive Capital Partners. A total of $19,537 was paid to acquire
such shares.
Funds used for the purchase of 10,000 shares of Common Stock on
the open market reported herein under Item 4 were derived from available working
capital of Accretive Capital Partners. A total of $17,000 was paid to acquire
such shares.
Funds used for the purchase of 8,850 shares of Common Stock on
the open market reported herein under Item 4 were derived from available working
capital of Accretive Capital Partners. A total of $14,780 was paid to acquire
such shares.
Funds used for the purchase of 10,000 shares of Common Stock on
the open market reported herein under Item 4 were derived from available working
capital of Accretive Capital Partners. A total of $16,500 was paid to acquire
such shares.
Funds used for the purchase of 10,000 shares of Common Stock on
the open market reported herein under Item 4 were derived from available
personal funds of Mr. Fearon. A total of $15,000 was paid to acquire such
shares.
Funds used for the purchase of 5,600 shares of Common Stock on
the open market reported herein under Item 4 were derived from available
personal funds of Mr. Fearon. A total of $8,400 was paid to acquire such
shares.
Item 4. Purpose of Transaction.
Item 4 is hereby amended and restated as follows:
The Reporting Persons acquired the securities of the Company
that they beneficially own for the investment purposes as they believe that the
Common Stock was undervalued and represented an attractive investment.
On January 25, 2012, Accretive Capital Partners acquired 45,000
shares of Series A Preferred Stock from ARC China, Inc., a Shanghai corporation
(“ARC China”), through a private transaction. In connection with the share purchase, ARC China assigned its right to cause
the Company to appoint or elect one person designated by ARC China to the
Company's Board of Directors under certain Securities Purchase Agreement, dated
May 27, 2010, by and among the Company and certain investors, to Accretive
Capital Partners. Accretive Capital Partners thereafter designated Mr. Fearon as
the candidate to be elected to the Company’s Board of Directors. For more
information about the Securities Purchase Agreement, please refer to the
Company’s Current Report on Form 8-K filed on June 3, 2010.
5
On November 19, 2014, Accretive Capital Partners purchased
11,425 shares of Common Stock on the open market.
On November 20, 2014, Accretive Capital Partners purchased
10,000 shares of Common Stock on the open market.
On November 20, 2014, Accretive Capital Partners purchased
8,850 shares of Common Stock on the open market.
On November 21, 2014, Accretive Capital Partners purchased
10,000 shares of Common Stock on the open market.
On December 17, 2014, Mr. Fearon purchased 10,000 shares of
Common Stock on the open market.
On December 29, 2014, Mr. Fearon purchased 5,600 shares of
Common Stock on the open market.
The Reporting Persons intend to review their investment in the
Company on a continuing basis. Subject to applicable legal requirements, the
Reporting Persons may purchase additional securities or dispose of all or a
portion of their securities of the Company from time to time in open market or
private transactions, depending on their evaluation of the Company’s business,
prospects and financial condition, the market for the Company’s securities,
other developments concerning the Company and general economic, money market and
stock market conditions.
While the Reporting Persons hold their stake for investment
purposes, the Reporting Persons or its representatives may continue to conduct
discussions from time to time with management and the board of directors of the
Company, and may conduct discussions with other stockholders of the Company,
prospective acquirers of the Company, or other relevant parties, in each case,
relating to matters that may include the strategic plans, strategy, assets,
business, financial condition, operations, and capital structure of the
Company.
In addition to the foregoing, without limitation, the Reporting
Persons may engage in discussions with management, the board of directors,
stockholders of the Company, prospective acquirers of the Company, and other
relevant parties or take other actions through their representatives concerning
any extraordinary corporate transaction (including but not limited to a merger
or acquisition) or the business, operations, assets, strategy, future plans,
prospects, corporate structure, board composition, management, capitalization,
dividend policy, charter, bylaws, corporate documents, agreements, de-listing or
de-registration of the Company. The Reporting Persons expect to conduct
discussions with other stockholders, potential acquirers of the Company, and
other relevant parties regarding financial or strategic acquisitions of or joint
ventures with the Company or other similar arrangements. There is no assurance
that these discussions would lead to a definitive transaction.
The Reporting Persons may also engage the Company, other
stockholders of the Company, prospective acquirers of the Company, or other
relevant parties in discussions that may include one or more of the other
actions described in subsections (a) through (j) of Item 4 of Schedule 13D.
6
Other than as described above in this Item 4 or as would occur
upon completion of any of the actions discussed herein, the Reporting Persons do
not have any present plan or proposal relating to or that would result in any of
the events or matters described in part (a) through (j) of Item 4 of Schedule
13D.
Item 5. Interest in Securities of the Issuer.
Item 5 is hereby amended and restated as follows:
(a) – (b) As of the date of this Amendment No. 4, Accretive
Capital Partners beneficially owns 2,078,356 shares of the Common Stock,
including 477,500 shares of Common Stock issuable upon conversion of 47,750
shares of Series A Preferred Stock at any time, at the option of Accretive
Capital Partners, on a 1-for-10 basis, representing approximately 11.86% of the
outstanding shares of the Common Stock of the Company. However, the conversion
of Series A Preferred Stock is subject to Section 4(f) of the Certificate of
Designation setting forth the designation and rights of the Series A Preferred
Stock, under which, the number of shares of the Common Stock outstanding
immediately after giving effect to the issuance of shares of Common Stock
issuable upon conversion of Series A Preferred Stock held by Accretive Capital
Partners cannot be more than 9.99% . By virtue of his direct and indirect
control of Accretive Capital Management and Accretive Capital Partners, Mr.
Fearon is deemed to have sole voting and dispositive powers with respect to the
shares of Common Stock beneficially owned by Accretive Capital Partners, as to
which Accretive Capital Management and Accretive Capital Partners are deemed to
have shared voting and dispositive powers.
In addition, Mr. Fearon individually owns 109,200 shares of
Common Stock representing 0.62% of the outstanding shares of the Company, as to
which he has sole voting and dispositive powers.
(c) Except as described above in Item 4 of this Amendment, the
Reporting Persons did not effect any transactions in the Company’s securities
within the past 60 days.
(d) None.
(e) Not applicable.
Item 7. Material to be Filed as Exhibits.
7
SIGNATURES
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement is true,
complete and correct.
Dated: July 22, 2015
| |
Accretive Capital Partners, LLC |
| |
Accretive Capital Management, LLC |
| |
|
| Signature |
/s/ Richard E. Fearon, Jr. |
| |
Richard E. Fearon, Jr., as the managing partner
of |
| |
Accretive Capital Management, the manager of
Accretive |
| |
Capital Partners |
| |
|
| |
|
| |
Richard E. Fearon, Jr. |
| |
|
| Signature |
/s/ Richard E. Fearon, Jr.
|
8
Exhibit 99.1
JOINT FILING AGREEMENT
The undersigned hereby agree, pursuant to Rule 13d-1(k) of the
Securities Exchange Act of 1934, as amended, to file a joint statement on
Schedule 13D (including amendments thereto) pertaining to their beneficial
ownership of shares of Common Stock of Nutrastar International Inc.
This agreement may be terminated for any reason by any party
hereto immediately upon the personal delivery or facsimile transmission of
notice to that effect to the other parties hereto.
Date: July 22, 2015
| |
Accretive Capital Partners, LLC |
| |
Accretive Capital Management, LLC |
| |
|
| Signature |
/s/ Richard E. Fearon, Jr. |
| |
Richard E. Fearon, Jr., as the managing partner
of |
| |
Accretive Capital Management, the manager of
|
| |
Accretive Capital Partners |
| |
|
| |
|
| |
Richard E. Fearon, Jr. |
| |
|
| Signature |
/s/ Richard E. Fearon, Jr.
|
| |
|
| |
|